RaQualia Pharma Inc. Logo

RaQualia Pharma Inc.

An R&D firm discovering novel small molecules for out-licensing to pharma partners.

4579 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
名古屋市中村区名駅南一丁目21番19号
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

RaQualia Pharma Inc. is a research and development-focused drug discovery company that originated as a spin-off from Pfizer's research laboratories. The company specializes in the discovery and early-stage development of novel pharmaceutical compounds, or 'seeds' for new drugs, with a focus on small molecules. Its primary business model involves creating these development compounds and then generating revenue through out-licensing agreements and partnerships with other pharmaceutical companies for late-stage development and commercialization. RaQualia actively leverages an open collaboration network with academic and industry partners to advance its pipeline. The company is also expanding into new therapeutic modalities, such as targeted protein degradation, to address previously 'undruggable' targets.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 08:58
Report Publication Announcement
確認書
Japanese 8.2 KB
2025-08-14 08:57
Interim Report
半期報告書-第18期(2025/01/01-2025/12/31)
Japanese 229.8 KB
2025-04-18 08:30
Major Shareholding Notification
臨時報告書
Japanese 21.1 KB
2025-03-31 09:01
Registration Form
訂正有価証券届出書(参照方式)
Japanese 155.4 KB
2025-03-31 08:31
Registration Form
訂正確認書
Japanese 8.2 KB
2025-03-31 08:30
Annual Report
訂正有価証券報告書-第17期(2024/01/01-2024/12/31)
Japanese 811.9 KB
2025-03-26 08:05
Regulatory News Service
訂正有価証券届出書(参照方式)
Japanese 158.4 KB
2025-03-26 07:52
Post-Annual General Meeting Information
臨時報告書
Japanese 22.7 KB
2025-03-26 07:51
Registration Form
確認書
Japanese 8.2 KB
2025-03-26 07:50
Governance Information
内部統制報告書-第17期(2024/01/01-2024/12/31)
Japanese 23.1 KB
2025-03-26 07:49
Annual Report
有価証券報告書-第17期(2024/01/01-2024/12/31)
Japanese 1.4 MB
2025-03-21 07:30
Registration Form
有価証券届出書(参照方式)
Japanese 282.6 KB
2024-12-13 08:00
Board/Management Information
臨時報告書
Japanese 20.7 KB
2024-10-01 09:04
Share Issue/Capital Change
訂正臨時報告書
Japanese 35.8 KB
2024-09-13 08:31
Share Issue/Capital Change
臨時報告書
Japanese 37.9 KB

Automate Your Workflow. Get a real-time feed of all RaQualia Pharma Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for RaQualia Pharma Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
A holding company driving regional growth by supporting construction, HR, and nursing care businesses.
Japan 7369
Mendus Logo
Developing immunotherapies using dendritic cells to prevent cancer recurrence and improve survival.
Sweden IMMU
Develops AI-driven, glasses-free 3D holographic displays for the defense sector.
United States of America N/A
MicroAd,Inc. Logo
Data-driven marketing tech providing DSP and SSP solutions for digital advertising.
Japan 9553
Microwave Chemical Co., Ltd. Logo
Innovating chemical and metal processing with an eco-friendly microwave platform.
Japan 9227
A think tank providing research, consulting, and ICT solutions to public & private sectors.
Japan 3636
Modalis Therapeutics Corporation Logo
Develops epigenome editing therapies for genetic muscular, heart, and CNS disorders.
Japan 4883
Model Solution Co., Ltd. Logo
One-stop prototyping & low-volume production for IT, electronics, and medical hardware.
South Korea 417970
Modus Therapeutics Holding AB Logo
Developing sevuparin, a polysaccharide for sepsis, septic shock, and chronic inflammation.
Sweden MODTX
Molecure S.A. Logo
Develops first-in-class small molecule drugs for oncology and inflammatory/fibrotic diseases.
Poland MOC

Talk to a Data Expert

Have a question? We'll get back to you promptly.